A jury awarded Retractable Technologies Inc. more than $113 million after it determined a competitor attempted to obtain a monopoly in the plastic safety syringe market. Retractable Technologies sued ...

VanishPoint® syringe sales have historically comprised most of our sales. VanishPoint® syringe sales were 89.9%, 84.9%, and 85.6% of our revenues in 2017, 2018, and 2019. As we have previously ...

Retractable Technologies (NYSE:RVP) its VanishPoint safety syringes are not part of a safety advisory issued by the FDA on Thursday about suspected performance problems with certain syringes ...

Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed ...

In the beginning, there was unlimited promise. A startup born out of an innovative mind and nurtured with federal grants was setting up shop in, of all places, Little Elm—a tiny speck of a suburb on ...

Shares of Retractable Technologies, Inc. RVP have risen 1.5% since the company released its quarterly results for the period ended Sept. 30, 2025, outperforming the S&P 500 Index, which declined 1.7% ...

A federal judge has ordered Becton Dickinson & Co. to pay $340 million to Retractable Technologies, Inc. (RVP) in a long-running dispute over the smaller company's allegations of false advertising. In ...

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2019. Further details concerning the ...

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports that the FDA Safety Communication “Evaluating Plastic Syringes Made in China for Potential Device ...